Viplib IV infusion 400 units, containing Velaglucerase alpha (genetically recombined), is manufactured by Takeda Pharmaceutical. This injectable drug, with YJ code 3959416F1020 and standard 400 units x 1 bottle, is an enzyme replacement therapy used for the long-term treatment of Type 1 Gaucher disease.
Viplib IV infusion 400 units
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).